Histologic subtype of cutaneous immune-related adverse events predicts overall survival in patients receiving immune checkpoint inhibitors - 19/08/22

Kelsey E. Hirotsu, MD ^a, Madeleine K.D. Scott, BS ^b, Cesar Marquez, PhD ^b, Anhthy T. Tran, MSN ^a, Kerri E. Rieger, MD, PhD ^{a, c}, Roberto A. Novoa, MD ^{a, c}, William H. Robinson, MD, PhD ^{d, e}, Bernice Y. Kwong, MD ^a, Lisa C. Zaba, MD, PhD ^{a, ⁎}

^a Department of Dermatology, Stanford University School of Medicine, Palo Alto, California 

^b Department of BioPhysics, Stanford University School of Medicine, Palo Alto, California 

^c Department of Pathology, Stanford University School of Medicine, Stanford, California 

^d Division of Immunology & Rheumatology, Department of Medicine, Stanford University School of Medicine, Stanford, California 

^e VA Palo Alto Health Care System, Palo Alto, California 

^∗Correspondence to: Lisa C. Zaba, MD, PhD, Department of Dermatology, Stanford University School of Medicine, 780 Welch Road, Suite CJ CJ220I, Palo Alto, CA 94304Department of DermatologyStanford University School of Medicine780 Welch Road, Suite CJ CJ220IPalo AltoCA94304